RBC Capital Sticks to Their Buy Rating for Integral Diagnostics Ltd. (IDX)


RBC Capital Sticks to Their Buy Rating for Integral Diagnostics Ltd. (IDX)

Filter, analyze, and streamline your search for investment opportunities with TipRanks' Stock Screener.

According to TipRanks, Wong-Pan is a 2-star analyst with an average return of -0.2% and a 48.28% success rate. Wong-Pan covers the Healthcare sector, focusing on stocks such as Nanosonics Limited, Ansell, and Cochlear Limited.

Integral Diagnostics Ltd. has an analyst consensus of Strong Buy, with a price target consensus of A$3.27, representing a 42.17% upside. In a report released yesterday, Jefferies also maintained a Buy rating on the stock with a A$3.60 price target.

IDX market cap is currently A$933.3M and has a P/E ratio of 103.29.

Previous articleNext article

POPULAR CATEGORY

corporate

12770

tech

11464

entertainment

15937

research

7363

misc

16759

wellness

12853

athletics

16863